Trial · NCT07902999
HB0025-C-0301: A Study to Investigate HB0025 Combined With Chemotherapy as First-Line Treatment for Advanced or Recurrent MMR-proficient Endometrial Cancer
NCT07902999, Phase 3, Recruiting, Shanghai Huaota Biopharmaceutical Co., Ltd.
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. HB0025-C-0301: A Study to Investigate HB0025 Combined With Chemotherapy as First-Line Treatment for Advanced or Recurrent MMR-proficient Endometrial Cancer. Trials, record NCT07902999. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07902999
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- HB0025-C-0301: A Study to Investigate HB0025 Combined With Chemotherapy as First-Line Treatment for Advanced or Recurrent MMR-proficient Endometrial Cancer
- NCT number
- NCT07902999
- Status
- Recruiting
- Phases
- Phase 3
- Enrollment
- 333 participants, estimated
- Lead sponsor
- Shanghai Huaota Biopharmaceutical Co., Ltd.
- Conditions
- First-line pMMR Endometrial Cancer
- Interventions
- HB0025 Injection, Paclitaxel injection, Carboplatin injection, Placebo matching HB0025
- First posted
- 2026-10-29
- Last updated
- 2026-10-29
Source ClinicalTrials.gov
Registered outcomes11
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Progression-free survival (PFS) | Up to 34 months | PFS is defined as the time from the date of randomization till the first documentation of disease progression (per RECIST v1.1 criteria) assessed by the Blinded Independent Central Review or death due to any cause (whichever occurs first) |
| Secondary | Progression-free survival (PFS) | Up to 34 months | PFS is defined as the time from the date of randomization till the first documentation of disease progression (per RECIST v1.1 criteria) assessed by the investigator or death due to any cause (whichever occurs first) |
| Secondary | Objective Response Rate (ORR) | Up to 34 months | ORR is defined as the proportion of subjects achieving the best overall response (BOR) as complete response (CR) or partial response (PR) according to RECIST 1.1 by investigator or Blinded Independent Central Review. |
| Secondary | Disease control rate (DCR) | Up to 34 months | DCR defined as the number of patients were confirmed CR or PR or stable disease(SD) according to RECIST 1.1 by investigator or Blinded Independent Central Review divided by the patients with at least one tumour evaluation. |
| Secondary | Duration of response (DOR) | Up to 34 months | DOR is defined as the time from the first record of CR or PR to the first record of disease progression as evaluated by investigators or Blinded Independent Central Review according to RECIST v1.1 or death. |
| Secondary | Time to Progression(TTP) | Up to 34 months | TTP is defined as the time from the time of randomization to the occurrence of disease progression according to Recist 1.1 by investigator or Blinded Independent Central Review. |
| Secondary | Overall Survival (OS) | Up to 34 months | OS is defined as the period from the start of randomization to the time of death due to any cause. |
| Secondary | Safety Assessment | Up to 34 months | The incidence, severity and outcome of adverse events (AE), serious adverse events (SAE), immune-related adverse events (irAE) and adverse events of special interest (AESI) per NCI-CTCAE V6.0. |
| Secondary | Cmax | Up to 34 months | Peak Plasma Concentration |
| Secondary | AUC | Up to 34 months | Area under the plasma concentration versus time curve |
1 to 10 of 11Source ClinicalTrials.gov
See all 11 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07902999
GET https://conductscience.org/api/trials/v1/NCT07902999/registered